Cutting-Edge Research Presented During Digestive Disease Week

Clinicians, researchers and scientists from around the world gathered for Digestive Disease Week® (DDW) 2011, the largest and most prestigious gastroenterology meeting, from May 7-10, 2011, at McCormick Place, Chicago, IL. DDW, which is jointly sponsored by the American Association for the Study of Liver Diseases, the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract, is the annual meeting of the AGA Institute.

AGA researchers are present exciting, cutting-edge data during the meeting that will help change the way physicians diagnose and treat GI disorders.

Late-Breaking Session

On May 10, 8:30 a.m. CT, Room S406B*, the AGA will feature its late-breaking clinical abstracts, which include exciting data on:

  • Effects of A3309, an Ileal Bile Acid Transporter Inhibitor, on Colonic Transit and Symptoms in Patients with Functional Constipation (Abstract #908). B. S. Wong et al.
  • High Sustained Virologic Response (SVR) Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin When Re-treated with Boceprevir (BOC) Plus Peginterferon Alfa-2A/Ribavirin (Abstract #903). S. L. Flamm et al.
  • Increased Risk of New or Missed Colorectal Cancers After Flexible Sigmoidoscopy Compared with Colonoscopy among Older Patients in the United States: A Population-Based Analysis of the SEER-Medicare Linked Database, 1998-2005 (Abstract #906). Y. R. Wang et al.
  • Obtaining SVR to Antiviral Therapy Highly Protects Patients with HCV Recurrence on the Graft after Liver Transplantation from Liver Related Death: Insights from the AISF-RECOLT-C Group (Abstract #905). M. Rendina et al.
  • Telaprevir-Based Regimens Substantially Improved SVR Rates Across All IL28B Genotypes in the ADVANCE Trial (Abstract #904). I. M. Jacobson et al.
  • Teduglutide, a Novel Analogue of Glucagon-like Peptide 2 (GLP-2), Is Effective and Safe in Reducing Parenteral Support Volume in Short Bowel Syndrome-Intestinal Failure Subjects: Results From a 24-Week, Placebo-Controlled Phase 3 Trial (STEPS) (Abstract #907). P. B. Jeppesen et al.

Plenary Sessions

During the Presidential Plenary Session, AGA Institute President, Ian L. Taylor, MD, PhD, AGAF, will focus on the latest research and clinical advances in the field of gastroenterology. Two additional plenary sessions feature noteworthy clinical and basic science research presented at DDW.

The Presidential Plenary Session presentations (May 9, 10 a.m. CT, Room S100AB) include:

  • Colon Cancer Screening. D. Provenzale.
  • Hepatitis C in Minority Populations. A. E. Reid.
  • Inflammatory Bowel Disease. S. R. Targan.
  • Endoscopic Ultrasound. R. H. Hawes.
  • The Brain-Gut Axis in Chronic GI Disease. E. A. Mayer.
  • The Role of Inflammation in the Causation of GI Cancers. S. E. Crowe.
  • Type II Diabetes Is a GI Disease and Should be Treated by Gastroenterologists. I. L. Taylor.
  • Impact of Health Reform on GI. J. V. Brill.
  • Towards Digestivism. P. B. Cotton.

The Basic Science Plenary Session presentations (May 8, 2:15 p.m. CT, Room S404) include:

  • Regeneration of Damaged Colonic Tissue by Transplantation of Colonic Epithelial Stem Cells Maintained and Expanded in Vitro (Abstract #534). S. Yui et al.
  • Neurotensin (NT) Receptor 1 (NTR1)-MicroRNA Networks in Human Colon Epithelial Cells. Characterization of Novel Pathways Connecting Neurotensin and Tumor Growth (Abstract #535). K. Bakirtzi et al.
  • Stem Cells, Growth Factor Signaling Pathways and Colon Cancer. R. J. Coffey.
  • A Chimeric Vaccine Prevents Primary and Recurrent Clostridium Difficile Infection (Abstract #536). H. Feng et al.
  • Restoration of Adult-Like Colonic Motility in Aged Transgenic Mice Expressing Phosphomimic HSP27 (Abstract #537). S. Somara et al.

The Clinical Plenary Session presentations (May 9, 8:30 CT, Room S105) include:

  • A Prospective Clinical Trial Shows that Intravenous N-acetylcysteine (NAC) Does Not Improve Survival in Pediatric Patients with Non-Acetaminophen Acute Liver Failure (Abstract #622). R. Squires et al.
  • Functional Disability and Informal Caregiving Among Older Patients with Decompensated Cirrhosis: An Analysis of the Health and Retirement Study (Abstract #623). M. O. Rakoski et al.
  • Abnormal Cerebral Hemodynamics in Hepatic Cirrhosis and Encephalopathy (Abstract #624). M. Green et al.
  • Telaprevir-Based Regimen in Genotype 1 Hepatitis C Virus-Infected Patients with Prior Null Response, Partial Response or Relapse to Peginterferon/Ribavirin: REALIZE Trial Final Results (Abstract #625). P. Pockros et al.
  • Anemia Had No Effect on Efficacy Outcomes in Treatment-Naïve Patients Who Received Telaprevir-Based Regimen in the ADVANCE and ILLUMINATE Phase 3 Studies (Abstract #626). F. Poordad et al.
  • Antiviral Treatment for Hepatitis C Virus Is Associated with a Reduced Risk of Hepatocellular Carcinoma in a National Cohort of U.S. Veterans (Abstract #627). J. R. Kramer et al.

Other exciting data will be presented during DDW, including 31 clinical symposia, 20 translational symposia, 11 research symposia and seven state-of-the-art lectures on a range of GI topics. Additionally, the AGA Institute will sponsor four curbside consultant sessions. A total of 11 focused research roundtables and focused clinical updates – breakfast sessions designed to help participants choose the must-see basic science and clinical research abstracts presented during DDW – will occur throughout the meeting.


Related Posts Plugin for WordPress, Blogger...
Be Sociable, Share!

About the Author

has written 157 posts on this blog.

Copyright © 2018 Medical Technology & Gadgets Blog All rights reserved.
Proudly powered by WordPress. Developed by Deluxe Themes